Cuvitru 1ml, 2ml, 4ml, 8ml,10ml Solution for subcutaneous injection
PDF Leaflet Revision Date: 29 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Replacement therapy for primary and secondary immunodeficiencies.
Dosage (summary)
Loading dose: 0.2-0.5 g/kg; Maintenance: 0.3-1.0 g/kg monthly.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use with caution in pregnancy; excreted in breast milk.
Key Drug Interactions
- Live attenuated virus vaccines
Contraindications
- Hypersensitivity to immunoglobulin
- Severe IgA deficiency
Common side effects
- Headache
- Dizziness
- Nausea
- Local reactions at infusion site
Counselling Points
- Monitor for adverse reactions
- Ensure adequate hydration before administration
- Record product name and batch number
Serious warnings
- Thromboembolism risk
- Renal complications
- Aseptic Meningitis Syndrome
Important Disclaimer
The Cuvitru 1ml, 2ml, 4ml, 8ml,10ml Solution for subcutaneous injection professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
